MedTrace Logo

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

NCT00821964 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2018-01-02

Study results available
· View outcomes & findings →

Summary

This phase II trial is studying the side effects of giving topical imiquimod together with Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) to see how well it works in treating patients with advanced breast cancer. Biological therapies, such as imiquimod, may stimulate the immune system to kill tumor cells. Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imiquimod together with Abraxane may kill more tumor cells.

Conditions

  • Male Breast Cancer
  • Recurrent Breast Cancer
  • Skin Metastases
  • Stage IV Breast Cancer

Interventions

DRUG

imiquimod

Given topically

DRUG

Abraxane

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

GENETIC

RNA analysis

Correlative studies

OTHER

immunoenzyme technique

Correlative studies

Sponsors & Collaborators

Principal Investigators

  • Lupe Salazar · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2012-11-30
Completion
2012-11-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00821964 on ClinicalTrials.gov